1.
Am J Gastroenterol
; 113(5): 775, 2018 05.
Artículo
en Inglés
| MEDLINE
| ID: mdl-29453380
2.
Trends Cancer
; 7(4): 283-292, 2021 04.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33317961
RESUMEN
Deeper and broader sequencing of circulating tumor DNA (ctDNA) has identified a wealth of cancer markers in the circulation, resulting in a paradigm shift towards data science-driven liquid biopsies in oncology. Although panel sequencing for actionable mutations in plasma is moving towards the clinic, the next generation of liquid biopsies is increasingly shifting from analyzing digital mutation signals towards analog signals, requiring a greater role for machine learning. Concomitantly, there is an increasing acceptance that these cancer signals do not have to arise from the tumor itself. In this Opinion, we discuss the opportunities and challenges arising from increasingly complex cancer liquid biopsy data.